The diagnostic yield of hereditary cancer genetic testing has improved over time as new technologies have been established. Despite these improvements, a substantial proportion of patients undergoing DNA testing for hereditary cancer still either receive inconclusive results or remain without a molecular diagnosis. This webinar will demonstrate how concurrent DNA and RNA genetic testing increases detection of clinically- actionable variants and reduces variants of unknown significance (VUS).
Objectives of this webinar include:
- Explain basic information about the role of RNA genetic testing in variant detection and classification
- Demonstrate the overall impact of concurrent DNA and RNA genetic testing on yield and VUS rates
- Discuss specific case examples
Join us to learn how your patients may benefit from the addition of RNA genetic testing.